Source: Eur Respir J , 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Helen E. Jo, Ian Glaspole, Christopher Grainge, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, E. Haydn Walters, Christopher Zappala, Heather Allan, Gregory J. Keir, Andrew Hayen, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Sacha Macansh, Tamera J. Corte. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J , 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 The European IPF Registry: Addressing challenges and characteristics of patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Treatment of patients with idiopathic pulmonary fibrosis in real-life setting: Results from the Latin American Pulmonary Fibrosis Registry REFIPI Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 IPF - Idiopathic Pulmonary Fibrosis Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152 Year: 2019 The Latin American Idiopathic Pulmonary Fibrosis Registry (REFIPI): Baseline Characteristics Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Impact of depression on patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Evaluation of Dyspnea Questionnaires in Patients with Idiopathic Pulmonary Fibrosis (IPF). Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 MMP7-degraded elastin is elevated in serum of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Diffuse pulmonary ossification in Idiopathic Pulmonary Fibrosis: Forli 10-year experience Source: International Congress 2017 – The wide spectrum of ILDs Year: 2017 Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: Comparison with COPD Source: Annual Congress 2013 –Exercise, physiotherapy techniques and assessment in different chronic conditions Year: 2013 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 Analysis of candidate genes of phenotypic expression in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Registry of idiopathic pulmonary fibrosis patients Source: International Congress 2016 – Russia Session Year: 2016